STOCK TITAN
  1. Home
  2. News
  3. JAZZ

Jazz Pharmaceuticals plc - JAZZ STOCK NEWS

Welcome to our dedicated news page for Jazz Pharmaceuticals plc (Ticker: JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Jazz Pharmaceuticals plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Jazz Pharmaceuticals plc's position in the market.

News
Jazz Pharmaceuticals to Present New Data Highlighting Advancements in Solid Tumors and Rare Blood Cancers at Upcoming Oncology Meetings
Rhea-AI Summary
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will present new trial results of investigational bispecific antibody zanidatamab at the 2023 San Antonio Breast Cancer Symposium (SABCS) and the 65th Annual American Society of Hematology (ASH) Annual Meeting, along with real-world data at the International Association for the Study of Lung Cancer (IASLC) 2023 North America Conference on Lung Cancer (NACLC).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.47%
Tags
conferences
-
News
Jazz Pharmaceuticals' 2022 Corporate Sustainability and Social Impact Report: Using Natural Resources Responsibly
Rhea-AI Summary
Jazz Pharmaceuticals (JAZZ) Corporate Sustainability and Social Impact Report 2022: Environmental Responsibility, Climate Strategy, and Water Management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
none
-
News
Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders
Rhea-AI Summary
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announces an exclusive global licensing agreement with Autifony Therapeutics Limited for up to $770.5 million to discover and develop drug candidates targeting ion channel targets associated with neurological disorders. Autifony will lead drug discovery and preclinical development activities, while Jazz will handle clinical development, manufacturing, and commercialization. Autifony is set to receive an upfront payment and potential milestone payments, with the total deal value including royalties on future net sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.3%
Tags
none
News
Jazz Pharmaceuticals Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
Rhea-AI Summary
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced 3Q23 total revenues of $972 million, with combined revenues from key growth drivers Xywav®, Epidiolex®, and Rylaze® increasing 24% year-over-year. The company is raising total and Oncology revenue guidance at the mid-points and plans to initiate zanidatamab rolling biologics license application (BLA) submission this year for accelerated approval in second-line (2L) biliary tract cancers (BTC).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.14%
Tags
earnings
-
News
Jazz Pharmaceuticals and MD Anderson Announce Five-Year Collaboration to Evaluate Zanidatamab in HER2-Expressing Cancers
Rhea-AI Summary
Jazz Pharmaceuticals plc and The University of Texas MD Anderson Cancer Center have entered a five-year strategic research collaboration to evaluate zanidatamab, an investigational HER2-targeted bispecific antibody, in multiple HER2-expressing cancers. The collaboration aims to investigate zanidatamab's potential as monotherapy and in combination with other treatments for patients with different tumor types and stages, including early-stage breast cancer, treatment-resistant cancers, and potentially rare, tissue-agnostic cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.66%
Tags
none
-
News
Jazz Pharmaceuticals to Participate in Upcoming November Investor Conferences
Rhea-AI Summary
Jazz Pharmaceuticals plc will participate in upcoming investor conferences including Jefferies London Healthcare Conference, 6th Annual Evercore ISI HealthCONx Conference, and 2023 BofA Leveraged Finance Conference. Audio webcasts of the presentations will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
conferences
News
Jazz Pharmaceuticals to Report 2023 Third Quarter Financial Results on November 8, 2023
Rhea-AI Summary
Jazz Pharmaceuticals will report its 2023 Q3 financial results on November 8, 2023. A live audio webcast will be hosted to discuss the results and provide a business update. Interested parties can access the webcast via the Investors section of the Jazz Pharmaceuticals website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
conferences earnings
-
News
Jazz Pharmaceuticals Presents Data Highlighting the Continued Need for Low-Sodium Treatment Option Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Real-World, Evidence-Based Approaches for Individualized Treatment in Adults with Narcolepsy at World Sleep 2023
Rhea-AI Summary
Jazz Pharmaceuticals presents new data on cardiovascular disease risk in patients with sleep disorders and the impact of sodium intake on cardiovascular health. The company also shares results from the TENOR study on individualized dosing regimens for narcolepsy patients transitioning to low-sodium Xywav.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.71%
Tags
none
-
News
Jazz Pharmaceuticals to Present Latest Advancements in Sleep Medicine at World Sleep 2023
Rhea-AI Summary
Jazz Pharmaceuticals to present 14 abstracts at World Sleep 2023 Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
conferences
News
Jazz Pharmaceuticals to Showcase Growing Impact in Solid Tumor Oncology Research at ESMO 2023
Rhea-AI Summary
Jazz Pharmaceuticals to present data on zanidatamab and Zepzelca at ESMO Congress 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.33%
Tags
none
Stock JAZZ logo
Jazz Pharmaceuticals plc

Nasdaq:JAZZ

JAZZ Rankings

#989 Ranked by Market Cap
#2855 Ranked by Stock Gains
N/A Ranked by Dividends

JAZZ Stock Data

6.89B
60.45M
2.82%
95.89%
5.23%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Ireland
Dublin

About JAZZ

jazz pharmaceuticals plc (nasdaq: jazz) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. we are a diverse company of over 875 employees focused on portfolio of products and/or product candidates in the areas of sleep, hematology/oncology and pain. founded in 2003 and headquartered in dublin, ireland, jazz pharmaceuticals has u.s. offices in palo alto, ca and philadelphia, pa, and has offices in various other locations in europe. the company’s maintains a highly collaborative and entrepreneurial culture where employees focus on how they accomplish success as well as what is done to accomplish results by operating in accordance with the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. we plan to build upon our portfolio of products through acquisition and/or in-licensing activities, and leveraging our uni